China Pharma Holdings (CPHI) Cash from Investing Activities Growth (3y) (2013 - 2025)
Powered by 
Analysis
China Pharma Holdings (CPHI) Cash from Investing Activities Growth (3y) (2013 - 2025) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn | 33.51% |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn | -51.98% |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | 21.19% |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn | -47.89% |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 27.70% |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn | - |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - | - |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn | -91.04% |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn | 33.61% |
| 10 | China Pharma Holdings | 31.39 Mn | 31.08 Mn | 83,566.00 | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -30.29% |
| Sep 30, 2025 | 33.81% |
| Jun 30, 2025 | 26.00% |
| Mar 31, 2025 | -247.41% |
| Dec 31, 2024 | -238.16% |
| Sep 30, 2024 | 26.46% |
| Dec 31, 2023 | -26.40% |
| Sep 30, 2023 | 36.17% |
| Jun 30, 2023 | 26.18% |
| Mar 31, 2023 | 29.28% |
| Dec 31, 2022 | 36.49% |
| Sep 30, 2022 | -174.57% |
| Jun 30, 2022 | -712.52% |
| Mar 31, 2022 | 73.40% |
| Dec 31, 2021 | 26.56% |
| Sep 30, 2021 | -398.89% |
| Dec 31, 2020 | 75.04% |
| Sep 30, 2020 | -155.71% |
| Jun 30, 2020 | -169.46% |
| Mar 31, 2020 | -135.50% |